Clinical , 7th Floor MEDICATION TRIALS: Tibotec. A single arm open P.I.: Salih Yasin, M.D. Enrollment open MEDICATION TRIALS: Treatment Naïve – Treatment Naïve – No PAST USE label study to assess the No PAST USE OF ANTIRETROVIRAL OF ANTIRETROVIRAL THERAPY pharmacokinetics of Rilpivirine Contact for further THERAPY in HIV-1 pregnant women. information: Yvette Rivero Eligibility: 305/243-2169 Women ≥ 18 years of age who have never taken antiretroviral drugs and are between 18-24 weeks pregnant. MEDICATION TRIALS: Tibotec. A single arm open P.I.: Salih Yasin, M.D. Enrollment open MEDICATION TRIALS: Treatment Treatment experienced (history label study to assess the experienced (history of Current or Past of Current or Past Use of pharmacokinetics of Contact for further Use of Antiretroviral Therapy) Antiretroviral Therapy) Darunavir/Ritonavir and/or information: Etravirine in HIV-1 pregnant Yvette Rivero Eligibility: women 305/243-2169 Women ≥ 18 years of age, with a history of taking antiretroviral drugs, who are between 18-24 weeks pregnant. Wohlfeiler, Piperato & Associates, LLC MEDICATION TRIALS: Treatment Sangamo Biosciences P.I.: Michael Wohlfeiler, Selected as a site – MEDICATION TRIALS: Treatment Naïve – Naïve – No PAST USE OF M.D. waiting for contract No PAST USE OF ANTIRETROVIRAL ANTIRETROVIRAL THERAPY (selected as site – details approval THERAPY pending) Contact for further information: Eligibility: Daniel Guzman, CRC Men and women > 305/538-1400 ext: 222 18 years of age never taken antiretroviral drugs and have a viral load > 2,500
Clinical , 7th Floor MEDICATION TRIALS: Treatment Naïve – No PAST USE OF ANTIRETROVIRAL THERAPY Tibotec. A single arm open label study to assess the pharmacokinetics of Rilpivirine in HIV-1 pregnant women. P.I.: Salih Yasin, M.D. Contact for further information: Yvette Rivero 305/243-2169 Enrollment open MEDICATION TRIALS: Treatment Naïve – No PAST USE OF ANTIRETROVIRAL THERAPY Eligibility: Women ≥ 18 years of age who have never taken antiretroviral drugs and are between 18-24 weeks pregnant. MEDICATION TRIALS: Treatment experienced (history of Current or Past Use of Antiretroviral Therapy) Tibotec. A single arm open label study to assess the pharmacokinetics of Darunavir/Ritonavir and/or Etravirine in HIV-1 pregnant women P.I.: Salih Yasin, M.D. Contact for further information: Yvette Rivero 305/243-2169 Enrollment open MEDICATION TRIALS: Treatment experienced (history of Current or Past Use of Antiretroviral Therapy) Eligibility: Women ≥ 18 years of age, with a history of taking antiretroviral drugs, who are between 18-24 weeks pregnant. Wohlfeiler, Piperato & Associates, LLC MEDICATION TRIALS: Treatment Naïve – No PAST USE OF ANTIRETROVIRAL THERAPY Sangamo Biosciences (selected as site – details pending) P.I.: Michael Wohlfeiler, M.D. Contact for further information: Daniel Guzman, CRC 305/538-1400 ext: 222 Selected as a site – waiting for contract approval MEDICATION TRIALS: Treatment Naïve – No PAST USE OF ANTIRETROVIRAL THERAPY Eligibility: Men and women > 18 years of age never taken antiretroviral drugs and have a viral load > 2,500
12-31-12%20FCHAR%20Inventory.docx